Mounjaro and Testosterone: What Happens to Your Hormone Levels

You've noticed your testosterone result has changed since starting Mounjaro

This is a question our prescribers hear most weeks, and it makes sense that it would come up. The connection between body weight and testosterone is well established in the clinical literature. In men, excess adipose tissue (body fat) converts testosterone to oestradiol via an enzyme called aromatase. The more fat tissue present, the more active this conversion tends to be, and circulating testosterone can fall as a result. When substantial weight loss occurs, that conversion slows, and total testosterone frequently rises. So if a blood test six months into tirzepatide treatment shows a higher testosterone reading than before, the most likely explanation is the weight loss itself, not anything Mounjaro does to hormone receptors directly.

The reverse can also be true in the short term. A very low calorie intake during rapid early weight loss occasionally produces a temporary dip in sex hormone levels in men, though this typically normalises as the body adjusts. If you have a result that concerns you, the right step is to discuss it with the clinician managing your treatment rather than drawing conclusions from a single data point. You can read more on the question of how Mounjaro affects testosterone in more detail, including what the available studies found.

What this means for women, particularly those with PCOS

The picture for women is different, and arguably more clinically relevant for many people asking about tirzepatide and testosterone. Polycystic ovary syndrome is associated with elevated androgens, including testosterone, and with insulin resistance. Tirzepatide works partly by improving insulin sensitivity alongside reducing appetite and body weight, and both mechanisms may reduce androgen excess in women with PCOS.

Clinical research into tirzepatide specifically in PCOS populations is still emerging, but evidence from semaglutide and from weight loss studies more broadly supports the idea that meaningful weight reduction improves androgen profiles and menstrual regularity in women with PCOS. The NHS notes that weight loss is one of the most effective interventions for managing PCOS symptoms — the mechanism through which a dual GIP and GLP-1 receptor agonist like tirzepatide achieves that weight loss does not fundamentally change that relationship. For women on Mounjaro and progesterone or combined hormonal preparations, there is a separate and well-evidenced point about oral contraceptive absorption during the early weeks of treatment, which is worth reviewing with a prescriber before starting.

None of this amounts to a licence claim. Mounjaro is authorised for weight management and type 2 diabetes. Treating PCOS or testosterone-related conditions as primary indications sits outside that licensed scope.

If you're on testosterone replacement therapy and considering Mounjaro

Men and women who are already prescribed testosterone replacement therapy (TRT) and are now thinking about starting Mounjaro face a practical question: is there a direct drug interaction? The short answer, based on what is currently known, is that no pharmacokinetic interaction between tirzepatide and exogenous testosterone has been identified. Tirzepatide is a peptide; it does not share metabolic pathways with testosterone through the cytochrome P450 enzyme system.

That said, the question of whether TRT doses need adjustment as body composition changes during treatment is entirely legitimate. As fat mass falls and lean mass is better preserved with adequate protein intake and resistance activity, the clinical picture for someone on TRT can shift. Testosterone levels (whether endogenous or supplemented) respond to body composition. The treating clinician managing your TRT should be kept informed when you start Mounjaro, and blood work reviewed at appropriate intervals. For a fuller look at the evidence on taking Mounjaro and testosterone together, including what monitoring looks like in practice, we have covered that ground separately.

If you are weighing up cost alongside all of this, the Mounjaro pricing context page explains honestly what private treatment includes and why the headline figure is not always what it appears.

What a prescriber needs to know before you start

Hormone-related history does not automatically rule out Mounjaro. What it does mean is that the prescribing clinician needs the full picture. Relevant information includes any current or recent hormone therapy, a known PCOS diagnosis, a history of hypogonadism, and any blood tests you already have. Tirzepatide is a dual GIP and GLP-1 receptor agonist with a well-characterised safety profile developed across thousands of adults in the SURMOUNT clinical programme, as detailed in NICE's appraisal of tirzepatide (TA1026). The NHS also provides a patient-level overview of tirzepatide, including its side effect profile, on the NHS tirzepatide medicines page.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who considers your individual history, not a screening algorithm. If your situation involves testosterone or hormone therapy, say so in the consultation; it is exactly the kind of clinical detail that shapes the right decision. Check your eligibility and start your free consultation to have that conversation with our prescribers.